Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. (linkinghub.elsevier.com)

Authors: Lu S … Xia MY Journal: The Lancet Published: 2026-05-31 DOI: https://doi.org/10.1016/S0140-6736(26)00966-9